Quantifying the treatment goals of people recently diagnosed with schizophrenia using best-worst scaling.

Bridges, John Fp; Beusterien, Kathleen; Heres, Stephan; Such, Pedro; Sánchez-Covisa, Joaquín; Nylander, Anna-Greta; Chan, Elcie; de Jong-Laird, Anne.

Affiliation

Bridges JF; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Beusterien K; Outcomes Research Strategies in Health, Washington DC, USA.
Heres S; Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany.
Such P; Global Medical Affairs, H. Lundbeck A/S, Valby, Denmark.
Sánchez-Covisa J; Medical Department, Otsuka Pharmaceutical Europe Ltd., Wexham, UK.
Nylander AG; Global Medical Affairs, H. Lundbeck A/S, Valby, Denmark.
Chan E; HEOR/Market Access, Otsuka Pharmaceutical Europe Ltd., Wexham, UK.
de Jong-Laird A; Medical Department, Otsuka Pharmaceutical Europe Ltd., Wexham, UK.

Patient Prefer Adherence ; 12: 63-70, 2018.

Article in En | MEDLINE | ID: mdl-29379273